1205533-60-3
1205533-60-3
Chemical Structure
Vesencumab
Synonym(s): MNRP-1685A
- CAS No.: 1205533-60-3
- Formula:N/A
- Molecular Weight:(145.262 kDa)
IUPAC Name: L-tryptophyl-L-histidyl-L-tryptophyl-L-leucyl-L-glutaminyl-L-leucine
SMILES: [Vesencumab]
Biological Activity: Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vesencumab | 99.34% | Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jonathan Stephens, et al. Rare disease landscape: will the blockbuster model be replaced? Expert Opinion on Orphan Drugs. Volume 2, 2014 - Issue 8.
- [2]. Zhang J, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022 Oct 25;11(21):3362. [Content Brief]
